A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients

Autor: Alejandro Pérez-Pitarch, Rafael Ferriols-Lisart, Manuel Alós-Almiñana, Miguel Mínguez-Pérez

Publikováno v: Revista Espanola de Enfermedades Digestivas, Vol 107, Iss 3, Pp 137-142 (2015)

Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. Th

Externí odkaz: https://doaj.org/article/44b7425ab7f14f6593b26781160eacac

Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis

Autor: Javier Aguilar-Serra, Ezequiel Marti-Bonmati, Cristina Trigo-Vicente, Julio Cortijo, Javier Milara, Alfonso Pastor-Clerigues, Manuel Alós-Almiñana, Vicente Gimeno-Ballester

Publikováno v: Journal of Comparative Effectiveness Research. 8:853-863

Aim: Osimertinib improves progression-free survival in first-line EGFR mutation–positive non-small-cell lung cancer. Materials & methods: A Markov cohort model including costs, utilities and disutilities, was conducted to estimate quality-adjusted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b663711e73d909a910abd9f048d4d9f
https://doi.org/10.2217/cer-2019-0029

Secondary adherence to beta-blockers after ST-elevation myocardial infarction without ventricular dysfunction

Autor: Manuel Alós-Almiñana, Ana López, José E. Peris

Publikováno v: MEDICINA CLINICA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-FISABIO. Repositorio Institucional de Producción Científica
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)

Introduction and objectives: Adequate medication intake affects treatment effectiveness. The aim of this study was to establish the impact of prescription and secondary adherence to beta-blockers on medium-and long-term and long-term cardiovascular o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa41fac6806891c009ae101108105a3a
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4490

Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma

Autor: Rafael Ferriols-Lisart, Javier F Belda-Nacher, Carlos Ezquer-Garin, Gerardo Aguilar-Aguilar, Manuel Alós-Almiñana, Jose-Antonio Carbonell

Publikováno v: Bioanalysis. 10:461-473

Aim: A simple, rapid, economical and sensitive HPLC-UV method was developed for the simultaneous quantification of ceftolozane and tazobactam in plasma samples. Methodology: After deproteinization followed by a liquid–liquid back-extraction, the co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a4ae0e1eb4e46e30e5633776642eef9
https://doi.org/10.4155/bio-2017-0257

Secondary adherence to beta-blockers after ST-elevation myocardial infarction without ventricular dysfunction

Autor: Ana, Padilla López, Manuel, Alós-Almiñana, José E, Peris

Publikováno v: Medicina clinica. 155(6)

Adequate medication intake affects treatment effectiveness. The aim of this study was to establish the impact of prescription and secondary adherence to beta-blockers on medium- and long-term and long-term cardiovascular outcomes, after a first type

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0f35039f534f1749ffa39bd2d9218a6f
https://pubmed.ncbi.nlm.nih.gov/31932044